ArticleDiscover oncology2025
Construction of a novel G2/M checkpoint-related gene signature for prognosis in hepatocellular carcinoma based on machine learning.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeHepatocellular carcinoma (HCC) is recognized as one of the most aggressive cancers worldwide. This study aims to discover novel biomarkers that can effectively stratify patients at high risk for HCC and facilitate personalized management.
methodsDifferentially expressed genes analysis was conducted to identify marker genes associated with HCC based on transcriptomic profiles from the TCGA-LIHC database. And then, we utilized the weighted correlation network analysis (WGCNA) to explore the correlation between various gene expression clustering modules based on the the identified differentially expressed genes above and clinical phenotypes. Subsequently, we integrated 10 machine learning algorithms into 117 combinations to establish the optimal model for predicting survival in HCC patients. Then, immune landscape was evaluated. Additionally, single-cell RNA sequencing analysis revealed the expression patterns of genes involved in model at single-cell resolution. Furthermore, the role of DTYMK was examined in vitro in two liver cancer cell lines.
resultsForty-eight G2/M checkpoint-related genes were identified as marker genes for HCC. Among these, STMN1, DTYMK, EZH2, PBK, and UCK2 were incorporated into a prognostic model (G2/MR), which demonstrated robust and reliable performance in predicting the survival rates of HCC patients. Individuals with high G2/MR scores exhibited shorter survival and higher regulatory T cells infiltration compared to those with low G2/MR scores. Silencing DTYMK arrested cell cycle and inhibited proliferation, migration, invasion, and colony formation in Huh-7 and PLC/PRF/5 cells.
conclusionOur study developed a five-gene risk score model that may serve as a valuable tool for prognostic assessment and personalized HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.